Amgen Exceeds Expectations in Q3 2025: Strong Product Performance and Increased Outlook
Reading Time: 3 minutes
The biotech giant Amgen (i) presented impressive results for the 3rd quarter of the current fiscal year on November 4, 2025. With total revenue of $9.6 billion, the company significantly exceeded analysts' consensus expectations of around $9.0 billion. This growth of 12% compared to the same period last year was primarily driven by a robust volume growth of 14%, which compensated for the negative impacts of lower net selling prices. The operational strength was also reflected in the adjusted earnings per share (Non-GAAP EPS), which at $5.64 clearly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
